Immuno-Real Time-PCR as a sensitive diagnostic tool: case of prion proteins.

Similar documents
number Done by Corrected by Doctor Ashraf Khasawneh

Biol212 Biochemistry of Disease Neurological Disorders: Prions

Glossary of relevant medical and scientific terms

Development of an Intravitam Diagnostic Test for Human Prion Diseases using Real Time QuIC and Enhanced QuIC Assays

similar version to the prion protein. Host proteins are correctly folded and prion proteins are

Quick facts about mad cow disease

Prion diseases or transmissible spongiform encephalopathies (TSEs)

New Ways of Prion Disease Detection & Diagnosis

London, 24 April 2001 EMEA/CPMP/BWP/819/01

Chronic Wasting Disease (CWD)

CJD DISEASE: Image Source: bestpractice.bmj.com

CREUTZFELDT-JAKOB DISEASE (CJD)

PRION 2017 Deciphering Neurodegenerative Disorders Edinburgh

CJD (Creutzfeldt-Jakob disease)

Prions: The Protein of Your Nightmares

LEVEL 3 CERTIFICATE / DIPLOMA 4463U10-1A. MEDICAL SCIENCE UNIT 1: Human Health and Disease

Appendix A: Disease-Specific Chapters

VIRUS VIROID PRION. Ms.Tanyaratana Dumkua Biology Department, Mahidolwittayanusorn School

Creutzfeldt-Jakob Disease Fact Sheet

PRIONIC DISEASES. fatal outcome in both human beings and animals. Etiology can be sporadic, genetic or acquired

Questions and answers on Bovine Spongiform Encephalopathies (BSE) and vaccines

Herpesvirus Infections of the Central Nervous System

Appendix B: Provincial Case Definitions for Reportable Diseases

Review Article ISSN : PRIONS-FRIENDS OR ENEMIES

The Centers for Disease Control and Prevention Report: Prion Disease Activities at CDC

Pathogen Safety and BSE / variant CJD

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING October2010. Issue Summary

Creutzfelt-Jakob Disease (CJD)

Human prion disease in Piemonte and Valle d Aosta, Italy: the experience of the reference center for human prion disease and a case description.

CREUTZFELDT-JAKOB DISEASE (CJD), CLASSIC

The Centers for Disease Control and Prevention Report: A CDC CJD Q&A

One of the classifications was if the virus is enveloped or naked.

Creutzfeldt-Jakob Disease Is A Rare Fatal Disease With No Treatment

FAMILY EDITION IN THIS ISSUE

Development of an ante-mortem & pre-symptomatic diagnostic test for human prion diseases using RT-QuIC & equic assays

Creutzfeldt-Jakob disease (CJD)

The Centers for Disease Control and Prevention Report: Prion Disease Activities at CDC

Registry of Creutzfeldt-Jakob disease and related disorders (19 years of activity: )

Viruses. Objectives At the end of this sub section students should be able to:

Creutzfeldt-Jakob Disease

Institute of Molecular and Cellular Biology FACULTY OF BIOLOGICAL SCIENCES. Lipid rafts in neurodegenerative diseases. Nigel M.

The Risk of vcjd Transmission by Blood and Suggested Public Policy Response

Objectives. Incident: cont. Incident: A Review of Creutzfeldt-Jakob Disease (CJD) with an Emphasis on Clinical Laboratory Issues

colorimetric sandwich ELISA kit datasheet

CPMP POSITION STATEMENT ON NEW VARIANT CJD and PLASMA-DERIVED MEDICINAL PRODUCTS

OPINION ON: THE IMPLICATIONS OF THE HOUSTON ET AL PAPER IN THE LANCET OF 16 SEPTEMBER 2000 ON THE TRANSMISSION OF BSE

Subclinical prion infection in humans and animals

Creutfeldt-Jakob draft policy December 2016

Genetic CJD INFORMATION SHEET 2 JANUARY Introduction to genetic CJD. Inheriting a risk of CJD

The Zombies of the Scientific Community Viruses and Other Acellular Infectious Agents. Acellular Agents

RIDASCREEN Risk Material 10/5

Joint UKBTS / NIBSC Professional Advisory Committee ( 1 ) Summary Sheet

Schedule of Accreditation

The Synthesis Report on the public consultation of the SCENIHR opinion on

Unusual infectious agents

Mandate and New Programs

Edinburgh Research Explorer

Creutzfeldt-Jakob Disease

Curriculum Vitae Gianluigi Zanusso, M.D., Ph.D.

Unusual infectious agents

Policy for Infection Prevention and Control of Transmissible Spongiform Encephalopathies (TSE)

Pathogens: Microorganisms that are capable of causing disease Infection: Results when a pathogen invades and begins growing within the host Disease:

PRION SURVEILLANCE IN PRIMARY IMMUNODEFICIENCY PATIENTS:

Cheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy

VOLUME 34 NUMBER 1 WINTER 1999

HEALTHCARE PROVIDER EDITION IN THIS ISSUE WINTER 2012 INTRODUCTION

7. CREUTZFELDT-JAKOB DISEASE (CJD) Cause/Epidemiology

Prions in the Urine of Patients with Variant Creutzfeldt Jakob Disease

Antemortem Diagnostics in Prion Disease. Danielle Gushue. A thesis submitted in partial fulfillment of the requirements for the degree of

Human Immunodeficiency Virus (HIV)

Creutzfeldt-Jakob Disease

Opinion on. The Safety of Human-derived Products with regard to Variant Creutzfeldt-Jakob Disease

How Now Mad Cow? Introduction to Prion Disease and Function. SHP Neurobiology of Development and Disease

WHO Guidelines on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies

colorimetric sandwich ELISA kit datasheet

Chapter 13B: Animal Viruses

Chapter 13 Viruses, Viroids, and Prions. Biology 1009 Microbiology Johnson-Summer 2003

Biol115 The Thread of Life"

human Total Cathepsin B Catalog Number: DY2176

Why Single Use of Endodontic Files Makes Sense For You and Your Patients

Continuous Production of Prions after Infectious Particles Are Eliminated: Implications for Alzheimer s Disease

( Sporadic Creutzfeldt-Jakob disease ) ( Infection control ) ( Decontamination )

MITOCW S05-L35

Chapter 19: Viruses. 1. Viral Structure & Reproduction. 2. Bacteriophages. 3. Animal Viruses. 4. Viroids & Prions

Overview of 2015 Zoonoses Data

Nigel Hooper. University of Manchester UK

Chapter 9. Protein Folding, Dynamics, and Structural Evolution

AlphaScreen : A Straightforward and Powerful Alternative to ELISA. Martina Bielefeld-Sévigny Ph.D., R&D Director

4 (online lecture) حسام أبو عوض. Raya Abu Tawileh. Anas Abu Humaidan

ABCD of CJD (the big picture of Creutzfeldt-Jakob disease)

Use of and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease

C-Peptide I and II (Rat) ELISA

Iatrogenic CJD INFORMATION SHEET 3 JANUARY Our first awareness of prion diseases

Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report

Alexander H Peden *, Deep P Sarode, Carl R Mulholland, Marcelo A Barria, Diane L Ritchie, James W Ironside and Mark W Head

CNS module / 3 rd year medicine. Dr Hamed Al-Zoubi Associate Prof. / Department of Microbiology

Mouse GLP-2 EIA. Cat. No. KT-374. For the quantitative determination of GLP-2 in mouse serum or plasma. For Research Use Only. 1 Rev.

Viruses defined acellular organisms genomes nucleic acid replicate inside host cells host metabolic machinery ribosomes

Chapter 19: Viruses. 1. Viral Structure & Reproduction. What exactly is a Virus? 11/7/ Viral Structure & Reproduction. 2.

Table of Contents (continued)

Transcription:

Immuno-Real Time-PCR as a sensitive diagnostic tool: case of prion proteins. Virginie Ruelle and Benaissa ElMoualij. Center of Research on Prion Protein, University of Liège, Liège, Belgium Freising-Weihenstephan 26th-30th March 2007 1

1. Introduction A. Prion diseases : Types Bovine Spongiform Encephalopathy (BSE) Scrapie Creutzfeldt-Jakob No-infectious CJD Infectious Variant CJD (vcjd) Transmissible neurodegenerative disorders which affect the Central Nervous System (CNS) 2

1. Introduction B. Prion diseases : Symptoms Dementia Are you afraid of BSE? Me? No, I m I m a rabbit! 3

1. Introduction B. Prion diseases : Symptoms Dementia Locomotive disorders 4

1. Introduction B. Prion diseases : Symptoms Dementia Locomotive disorders Spongiform pathology of brain Vacuole Aggregate Fatal 5

1. Introduction C. Prion diseases : Infectious agent Normal protein : PrP c. Cellular prion. No-pathogenic. Soluble Abnormal protein : PrP sc ou PrP. Scrapie Prion. Pathogenic. Relatively no-soluble. Proteinase K resistant PrP res res Sequence = Folding 6

1. Introduction C. Prion diseases : Infectious agent PrP c 7

1. Introduction C. Prion diseases : Infectious agent PrP c PrP sc 8

1. Introduction C. Prion diseases : Infectious agent PrP c PrP sc 9

1. Introduction C. Prion diseases : Infectious agent PrP c PrP sc 10

1. Introduction C. Prion diseases : Infectious agent PrP c PrP sc 11

1. Introduction C. Prion diseases : Infectious agent PrP c PrP sc 12

1. Introduction C. Prion diseases : Infectious agent PrP c PrP sc Aggregate 13

1. Introduction D. Prion diseases : vcjd Contamination 14 Ludlam CA et al. British Journal of Haematology, 132, 13 24.

1. Introduction D. Prion diseases : vcjd Contamination Confirmed cases Cow BSE 188.417 From 1987 Contaminated Food Human vcjd 198 From 1995 15 Ludlam CA et al. British Journal of Haematology, 132, 13 24.

1. Introduction D. Prion diseases : vcjd Contamination Confirmed cases Cow BSE 188.417 From 1987 Contaminated Food 31 Blood donors 66 Blood recipients Human vcjd 198 From 1995 Contaminated Blood 4 From 2004 Diagnostic 17

1. Introduction D. Prion diseases : vcjd Contamination New sensitive test to detect prion : Say Meuh Pré-clinical phase (LONG) Clinical Phase (SHORT) No Meuh!! Inoculation Ingestion of BSE contaminated food First Death clinical signs Disease blocking 18 Bruce ME et al. Immunol Today. 2000;21(9):442-6.

1. Introduction E. Prion diseases : Diagnostic Living : Symptoms Post-mortem : BRAIN - Histological coupe - Molecular diagnostic 19

Rapid BSE testing kits approved by the European Commission ELISA BioRad TeSeE Detection Kit ENFER TSE kit v.2.0 InPro CDI-5 Institut Pourquier Speed it BSE Prionics Check LIA Roche Applied Science PrioScreen Roboscreen BetaPrion BSE EIA test kit Western Blot Other Prionics Check Western Ceditect BSE test Prionics Check PrioStrip IDEXX Herdchek BSE Antigen Test Kit EIA 20

1. Introduction E. Prion diseases : Molecular Diagnostic SENSITIVITY Classical assays on PrP sc Western blot ELISA Threshold of sensitivity 1000-3000 IU/mL ~ 1000 IU/mL Clinical phase : > 100 IU/mL immuno-pcr Pré- Clinical phase : < 10 IU/mL 21 Barletta JM et al. J. Virol. Methods. 2005;127:154-164.

2. Immuno-PCR A. Principle : Detection antibody DNA PCR Antigen Capture Antibody Signal amplification Plate 22

2. Immuno-PCR A. Principle : Biotinylated Detection antibody B Antigen Capture Antibody Plate 23

2. Immuno-PCR A. Principle : Biotinylated Detection antibody B Strep Antigen Capture Antibody Plate 24

2. Immuno-PCR A. Principle : Chimeric DNA Nature Matrix Biotinylated Detection antibody B Strep Antigen Capture Antibody Plate Patent: EP1232283,2002-08-21. i-detect 25Company www.i-detect.eu

2. Immuno-PCR A. Principle : Nature Chimeric DNA Organisms Matrix A B C Synthetic Patent: EP1232283,2002-08-21. i-detect 26Company www.i-detect.eu

2. Immuno-PCR No-pathogenic B. Evaluation on human recombinant prion protein 4F7 PrP rec 1E5 B Strep Plate ELISA Detection limit ~ 10 ng/ml immuno-pcr Detection limit ~ 100pg/mL Improvement 100 x Cycle t 24 25 26 27 28 29 30 ipcrq 100 pg/ml Recombinante Prion Detection limit ELISA 10 ng/ml 31 0 0 1 2 3 4 5 6 7 Log C 2 1 Optical Density 27

2. Immuno-PCR Pathogenic C. Application : diagnostic of Creutzfeldt-Jakob Disease Gofflot S et al. Clinical chemistry. 2005;51(9):1605-11. 28

2. Immuno-PCR Pathogenic C. Application : diagnostic of Creutzfeldt-Jakob Disease Studied cases Gofflot S et al. Clinical chemistry. 2005;51(9):1605-11. 29

2. Immuno-PCR Pathogenic C. Application : diagnostic of Creutzfeldt-Jakob Disease Studied cases Gofflot S et al. Clinical chemistry. 2005;51(9):1605-11. 30

2. Immuno-PCR Pathogenic C. Application : diagnostic of Creutzfeldt-Jakob Disease Sample preparation Plate Middle frontal gyrus Diagnostic surgical biopsies Have been performed previously Homogenization PK digestion Concentration Dilution 31 Gofflot S et al. Clinical chemistry. 2005;51(9):1605-11.

2. Immuno-PCR Pathogenic C. Application : diagnostic of Creutzfeldt-Jakob Disease ELISA/iqPCR comparison Cycle threshold (Ct) 24 25 26 27 28 29 30 31 Prion in brain CJD n 1 ELISA 100x ipcrq 5.000x 2.0 1.5 1.0 0.5 32 0.0 1 10 100 1000 Dilution (1/x) Optical Density (450nm) Cycle threshold (Ct) 24 25 26 27 28 29 30 31 Prion in brain Control n 1 32 1 10 100 1000 0.0 Dilution (1/x) 2.0 1.5 1.0 0.5 Optical Density (450nm) 4F7 B Strep Improvement 50 x PrP rec 1E5 Plate Gofflot S et al. Clinical chemistry. 2005;51(9):1605-11. 32

2. Immuno-PCR Pathogenic C. Application : diagnostic of Creutzfeldt-Jakob Disease ELISA/iqPCR comparison Cycle threshold (Ct) 24 25 26 27 28 29 30 31 Prion in brain CJD n 1 ELISA 100x ipcrq 5.000x 2.0 1.5 1.0 0.5 32 0.0 1 10 100 1000 Dilution (1/x) Optical Density (450nm) Cycle threshold (Ct) Prion in brain Control n 1 to 7 24 2.0 25 26 27 1.5 28 29 30 1.0 31 32 33 0.5 34 35 36 1 10 100 1000 0.0 Dilution (1/x) Optical Density (450nm) 4F7 B Strep Improvement 50 x PrP rec 1E5 Plate Gofflot S et al. Clinical chemistry. 2005;51(9):1605-11. 33

2. Immuno-PCR Pathogenic C. Application : diagnostic of Creutzfeldt-Jakob Disease ELISA/iqPCR comparison Cycle threshold (Ct) 24 25 26 27 28 29 30 31 Prion in brain CJD n 1 ELISA 100x ipcrq 5.000x 2.0 1.5 1.0 0.5 32 0.0 1 10 100 1000 Dilution (1/x) Optical Density (450nm) 4F7 B Strep Improvement 50 x PrP rec 1E5 Plate Gofflot S et al. Clinical chemistry. 2005;51(9):1605-11. 34

2. Immuno-PCR Pathogenic Cycle threshold (Ct) Cycle threshold (Ct) Cycle threshold (Ct) Prion in brain CJD n 2 24 2.0 25 26 1.5 27 28 ipcrq 5.000x 1.0 29 30 ELISA 100x 0.5 31 32 0.0 1 10 100 1000 Dilution (1/x) Prion in brain CJD n 3 24 2.0 25 26 1.5 27 ipcrq 28 1.000x 1.0 29 30 31 32 ELISA 10x 0.5 0.0 1 10 100 1000 Dilution (1/x) Prion in brain CJD n 4 24 2.0 25 26 1.5 27 28 ipcrq 500x 1.0 29 ELISA 30 31 32 5x 0.5 0.0 1 10 100 1000 Dilution (1/x) C. Application : diagnostic of Creutzfeldt-Jakob Disease Validation 50 x 100 x 100 x 100 x ( ) ( ) ( ) Prion in brain CJD n 5 24 2.0 25 26 1.5 27 28 1.0 29 30 31 32 ipcrq ELISA 5.000x 50x 0.5 0.0 1 10 100 1000 Dilution (1/x) Prion in brain CJD n 6 24 2.0 25 26 1.5 27 28 ipcrq 1.000x 1.0 29 30 31 32 ELISA 10x 0.5 0.0 1 10 100 1000 Dilution (1/x) Prion in brain CJD n 7 100 x 20 x 24 2.0 25 26 1.5 27 28 29 ipcrq 1.000x 1.0 30 ELISA 50x 0.5 31 32 0.0 1 10 100 1000 Dilution (1/x) Optical Density (450nm) Optical Density (450nm) Optical Density (450nm) Cycle threshold (Ct) 24 25 26 27 28 29 30 31 Prion in brain CJD n 1 to 7 2.0 1.5 1.0 0.5 32 0.0 1 10 100 1000 Improvement 20 to 100 x 35 Optical Density (450nm) Gofflot S et al. Clinical chemistry. 2005;51(9):1605-11.

2. Immuno-PCR Pathogenic C. Application : diagnostic of Creutzfeldt-Jakob Disease Validation CJD Controls rec 1 2 3 4 5 6 7 1 2 3 4 5 6 7 75 50 37 25 20 10 Gofflot S et al. Clinical chemistry. 2005;51(9):1605-11. 36

2. Immuno-PCR Pathogenic C. Application : diagnostic of Creutzfeldt-Jakob Disease 75 50 37 25 20 10 Validation CJD Controls rec 1 2 3 4 5 6 7 1 2 24 3 4 5 6 7 Cycle threshold (Ct) 25 26 27 28 29 30 31 Prion in brain CJD n 4 ELISA 5x 2.0 1.5 1.0 0.5 32 0.0 1 10 100 1000 Dilution (1/x) 100 x ipcrq 500x Gofflot S et al. Clinical chemistry. 2005;51(9):1605-11. 37

2. Immuno-PCR Pathogenic C. Application : diagnostic of Creutzfeldt-Jakob Disease. Comparison of brain samples 7 patients with sporadic CJD / 7 controls using : ELISA Western-Blot immuno-pcr. All methods shows similar sensitivity and specificity (100% detected) Signal improvement compared to ELISA and Western-Blot ~ 100x on pathogenic protein (CJD). immuno-pcr as a new useful tool for ante-mortem PrPres detection 38

2. Immuno-PCR D. Protocol improvement vs reproducibility: Buffer/Antibodies/DNA/Plate controls Strep Plate Detection complexes 4F7 BStrep Plate 4F7 biotinylated39antibody Roboscreen

Background 8 controls Day n 1 1 at Ct=38 7 at Ct=40 Day n 2 1 at Ct=38,5 7 at Ct=40 Day n 3 1 > Ct=37 7 at Ct=40 40

Reproducibility 8 detection complexes Day n 1 8 Ct in [25-26] Day n 2 8 Ct in [25-26] Day n 3 8 Ct in [25-26,2] 41

2. Immuno-PCR E. Detection in blood: EUROPE 6 e Framework Programme 2007-2010 EUDICA LANCASTER UNIVERSITY Plasma lab Jozef Stefan Institute Ljubljana CHU Lyon National Institute of Psychiatry and Neurology BUDAPEST 42

2. Immuno-PCR E. Detection in blood: EUROPE 6 e Framework Programme 2007-2010 LANCASTER UNIVERSITY Plasma lab Jozef Stefan Institute Ljubljana CHU Lyon Diagnostic kits Creutzfeldt-Jakob Alzheimer Parkinson EUDICA National Institute of Psychiatry and Neurology BUDAPEST 43

3. Conclusions. Immuno-PCR as detection tool could be used to detect pathogenic and no-pathogenic forms of Prion protein (and others). Immuno-PCR as ultrasensitive tool Signal improvement compared to ELISA - 100x on pathogenic protein (CJD). Immuno-PCR with low background Buffers/Antibodies/DNA/plate improvement - Background near of a Ct= 40 - Reproductibility intra and inter-days. immuno-pcr as a new useful for ante-mortem PrPres detection IN BLOOD 44

Acknowledgements 45

Acknowledgements EUDICA LANCASTER UNIVERSITY Plasma lab Jozef Stefan Institute Ljubljana CHU Lyon National Institute of Psychiatry and Neurology BUDAPEST 46

Thank you for your attention Contacts : v.ruelle@ulg.ac.be www.i-detect.eu 47